Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 85 to 94 of 94 entries
Sorted by: Best Match Show Resources per page
Advancing to the era of cancer immunotherapy.

Cancer communications (London, England)

Wang Y, Wang M, Wu HX, Xu RH.
PMID: 34165252
Cancer Commun (Lond). 2021 Sep;41(9):803-829. doi: 10.1002/cac2.12178. Epub 2021 Jun 24.

Cancer greatly affects the quality of life of humans worldwide and the number of patients suffering from it is continuously increasing. Over the last century, numerous treatments have been developed to improve the survival of cancer patients but substantial...

Cite
Wang Y, Wang M, Wu HX, et al. Advancing to the era of cancer immunotherapy. Cancer Commun (Lond). 2021;41(9):803-829doi: 10.1002/cac2.12178.
Wang, Y., Wang, M., Wu, H. X., & Xu, R. H. (2021). Advancing to the era of cancer immunotherapy. Cancer communications (London, England), 41(9), 803-829. https://doi.org/10.1002/cac2.12178
Wang, Yun, et al. "Advancing to the era of cancer immunotherapy." Cancer communications (London, England) vol. 41,9 (2021): 803-829. doi: https://doi.org/10.1002/cac2.12178
Wang Y, Wang M, Wu HX, Xu RH. Advancing to the era of cancer immunotherapy. Cancer Commun (Lond). 2021 Sep;41(9):803-829. doi: 10.1002/cac2.12178. Epub 2021 Jun 24. PMID: 34165252; PMCID: PMC8441060.
Copy Download .nbib Format: NLM
[PD-L1 : a natural immunosuppressor related to carcinogenesis. A pathologist's point of view].

Revue medicale de Liege

Lacremans P, Detrembleur N, Dome F, Collins P, Delvenne P.
PMID: 34080369
Rev Med Liege. 2021 May;76(5):392-397.

The goal of this article is to emphasize the role of anatomopathology for the intratumoral detection of the immune checkpoint PD-L1. This molecule is one of the main targets in the anti-cancer immunotherapy. The binding of PD-L1 to its...

Cite
Lacremans P, Detrembleur N, Dome F, et al. Le PD-L1 : un immunosuppresseur naturel impliqué dans la carcinogenèse Le point de vue du pathologiste. [PD-L1 : a natural immunosuppressor related to carcinogenesis. A pathologist's point of view]. Rev Med Liege. 2021;76(5):392-397
Lacremans, P., Detrembleur, N., Dome, F., Collins, P., & Delvenne, P. (2021). Le PD-L1 : un immunosuppresseur naturel impliqué dans la carcinogenèse Le point de vue du pathologiste. [PD-L1 : a natural immunosuppressor related to carcinogenesis. A pathologist's point of view]. Revue medicale de Liege, 76(5), 392-397.
Lacremans, P, et al. "Le PD-L1 : un immunosuppresseur naturel impliqué dans la carcinogenèse Le point de vue du pathologiste." [PD-L1 : a natural immunosuppressor related to carcinogenesis. A pathologist's point of view]. Revue medicale de Liege vol. 76,5 (2021): 392-397.
Lacremans P, Detrembleur N, Dome F, Collins P, Delvenne P. Le PD-L1 : un immunosuppresseur naturel impliqué dans la carcinogenèse Le point de vue du pathologiste. [PD-L1 : a natural immunosuppressor related to carcinogenesis. A pathologist's point of view]. Rev Med Liege. 2021 May;76(5):392-397. French. PMID: 34080369.
Copy Download .nbib Format: NLM
[Immunotherapy adaptation in lung cancer during the COVID-19 pandemic].

Revue des maladies respiratoires

Travert C, Cannone P, Greillier L, Tomasini P.
PMID: 34246519
Rev Mal Respir. 2021 Nov;38(9):865-872. doi: 10.1016/j.rmr.2021.06.005. Epub 2021 Jun 30.

INTRODUCTION: COVID-19 pandemics required changes in medical practices. In thoracic oncology, pembrolizumab was doubled to 400mg every 6weeks, nivolumab to 480mg every 4weeks. The objective of our study was to assess the impact on quality of life, and on...

Cite
Travert C, Cannone P, Greillier L, et al. COVID-19 et cancer bronchique : adaptation des schémas d’immunothérapie et qualité de vie. [Immunotherapy adaptation in lung cancer during the COVID-19 pandemic]. Rev Mal Respir. 2021;38(9):865-872doi: 10.1016/j.rmr.2021.06.005.
Travert, C., Cannone, P., Greillier, L., & Tomasini, P. (2021). COVID-19 et cancer bronchique : adaptation des schémas d’immunothérapie et qualité de vie. [Immunotherapy adaptation in lung cancer during the COVID-19 pandemic]. Revue des maladies respiratoires, 38(9), 865-872. https://doi.org/10.1016/j.rmr.2021.06.005
Travert, C, et al. "COVID-19 et cancer bronchique : adaptation des schémas d’immunothérapie et qualité de vie." [Immunotherapy adaptation in lung cancer during the COVID-19 pandemic]. Revue des maladies respiratoires vol. 38,9 (2021): 865-872. doi: https://doi.org/10.1016/j.rmr.2021.06.005
Travert C, Cannone P, Greillier L, Tomasini P. COVID-19 et cancer bronchique : adaptation des schémas d’immunothérapie et qualité de vie. [Immunotherapy adaptation in lung cancer during the COVID-19 pandemic]. Rev Mal Respir. 2021 Nov;38(9):865-872. doi: 10.1016/j.rmr.2021.06.005. Epub 2021 Jun 30. French. PMID: 34246519; PMCID: PMC8241593.
Copy Download .nbib Format: NLM
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.

Journal for immunotherapy of cancer

Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK.
PMID: 34389617
J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2021-002597.

Breast cancer has historically been a disease for which immunotherapy was largely unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with chemotherapy for the treatment of advanced/metastatic triple-negative breast cancer (TNBC) has demonstrated efficacy, including longer...

Cite
Emens LA, Adams S, Cimino-Mathews A, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021;9(8)doi: 10.1136/jitc-2021-002597.
Emens, L. A., Adams, S., Cimino-Mathews, A., Disis, M. L., Gatti-Mays, M. E., Ho, A. Y., Kalinsky, K., McArthur, H. L., Mittendorf, E. A., Nanda, R., Page, D. B., Rugo, H. S., Rubin, K. M., Soliman, H., Spears, P. A., Tolaney, S. M., & Litton, J. K. (2021). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. Journal for immunotherapy of cancer, 9(8), . https://doi.org/10.1136/jitc-2021-002597
Emens, Leisha A, et al. "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer." Journal for immunotherapy of cancer vol. 9,8 (2021). doi: https://doi.org/10.1136/jitc-2021-002597
Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2021-002597. PMID: 34389617; PMCID: PMC8365813.
Copy Download .nbib Format: NLM
An NIR-Fluorophore-Based Theranostic for Selective Initiation of Tumor Pyroptosis-Induced Immunotherapy.

Small (Weinheim an der Bergstrasse, Germany)

Wang K, Xiao X, Jiang M, Li J, Zhou J, Yuan Y.
PMID: 34323375
Small. 2021 Sep;17(36):e2102610. doi: 10.1002/smll.202102610. Epub 2021 Jul 29.

Pyroptosis is an inflammatory form of programmed cell death that can effectively eliminate malignant cells and boost anticancer immunity. However, most of the current pyroptosis inducers lack cell selectivity, which may cause severe side effects for cancer therapy. In...

Cite
Wang K, Xiao X, Jiang M, et al. An NIR-Fluorophore-Based Theranostic for Selective Initiation of Tumor Pyroptosis-Induced Immunotherapy. Small. 2021;17(36):e2102610doi: 10.1002/smll.202102610.
Wang, K., Xiao, X., Jiang, M., Li, J., Zhou, J., & Yuan, Y. (2021). An NIR-Fluorophore-Based Theranostic for Selective Initiation of Tumor Pyroptosis-Induced Immunotherapy. Small (Weinheim an der Bergstrasse, Germany), 17(36), e2102610. https://doi.org/10.1002/smll.202102610
Wang, Kewei, et al. "An NIR-Fluorophore-Based Theranostic for Selective Initiation of Tumor Pyroptosis-Induced Immunotherapy." Small (Weinheim an der Bergstrasse, Germany) vol. 17,36 (2021): e2102610. doi: https://doi.org/10.1002/smll.202102610
Wang K, Xiao X, Jiang M, Li J, Zhou J, Yuan Y. An NIR-Fluorophore-Based Theranostic for Selective Initiation of Tumor Pyroptosis-Induced Immunotherapy. Small. 2021 Sep;17(36):e2102610. doi: 10.1002/smll.202102610. Epub 2021 Jul 29. PMID: 34323375.
Copy Download .nbib Format: NLM
M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer.

Annals of medicine

JiaWei Z, ChunXia D, CunDong L, Yang L, JianKun Y, HaiFeng D, Cheng Y, ZhiPeng H, HongYi W, DeYing L, ZhiJian L, Xiao X, QiZhao Z, KangYi X, WenBing G, Ming X, JunHao Z, JiMing B, ShanChao Z, MingKun C.
PMID: 34032524
Ann Med. 2021 Dec;53(1):730-740. doi: 10.1080/07853890.2021.1924396.

BACKGROUND: Prostate cancer (PCa) is poor response to the immunotherapy for its high heterogeneity of immune microenvironment. In this study, we aim to introduce a new immune subtype for PCa involving M2 tumour associated macrophages METHODS: Three hundred and...

Cite
JiaWei Z, ChunXia D, CunDong L, et al. M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer. Ann Med. 2021;53(1):730-740doi: 10.1080/07853890.2021.1924396.
JiaWei, Z., ChunXia, D., CunDong, L., Yang, L., JianKun, Y., HaiFeng, D., Cheng, Y., ZhiPeng, H., HongYi, W., DeYing, L., ZhiJian, L., Xiao, X., QiZhao, Z., KangYi, X., WenBing, G., Ming, X., JunHao, Z., JiMing, B., ShanChao, Z., & MingKun, C. (2021). M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer. Annals of medicine, 53(1), 730-740. https://doi.org/10.1080/07853890.2021.1924396
JiaWei, Zhou, et al. "M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer." Annals of medicine vol. 53,1 (2021): 730-740. doi: https://doi.org/10.1080/07853890.2021.1924396
JiaWei Z, ChunXia D, CunDong L, Yang L, JianKun Y, HaiFeng D, Cheng Y, ZhiPeng H, HongYi W, DeYing L, ZhiJian L, Xiao X, QiZhao Z, KangYi X, WenBing G, Ming X, JunHao Z, JiMing B, ShanChao Z, MingKun C. M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer. Ann Med. 2021 Dec;53(1):730-740. doi: 10.1080/07853890.2021.1924396. PMID: 34032524; PMCID: PMC8158194.
Copy Download .nbib Format: NLM
Real-world evidence costs of allergic rhinitis and allergy immunotherapy in the commercially insured United States population.

Current medical research and opinion

Tkacz JP, Rance K, Waddell D, Aagren M, Hammerby E.
PMID: 33754932
Curr Med Res Opin. 2021 Jun;37(6):957-965. doi: 10.1080/03007995.2021.1903848. Epub 2021 Apr 02.

OBJECTIVE: To assess total and allergic rhinitis (AR)-related healthcare costs among AR patients residing in the United States with a focus on patients persisting with AIT.METHODS: AR patients were identified in the IBM MarketScan database between 1 January 2014...

Cite
Tkacz JP, Rance K, Waddell D, et al. Real-world evidence costs of allergic rhinitis and allergy immunotherapy in the commercially insured United States population. Curr Med Res Opin. 2021;37(6):957-965doi: 10.1080/03007995.2021.1903848.
Tkacz, J. P., Rance, K., Waddell, D., Aagren, M., & Hammerby, E. (2021). Real-world evidence costs of allergic rhinitis and allergy immunotherapy in the commercially insured United States population. Current medical research and opinion, 37(6), 957-965. https://doi.org/10.1080/03007995.2021.1903848
Tkacz, Joseph P, et al. "Real-world evidence costs of allergic rhinitis and allergy immunotherapy in the commercially insured United States population." Current medical research and opinion vol. 37,6 (2021): 957-965. doi: https://doi.org/10.1080/03007995.2021.1903848
Tkacz JP, Rance K, Waddell D, Aagren M, Hammerby E. Real-world evidence costs of allergic rhinitis and allergy immunotherapy in the commercially insured United States population. Curr Med Res Opin. 2021 Jun;37(6):957-965. doi: 10.1080/03007995.2021.1903848. Epub 2021 Apr 02. PMID: 33754932.
Copy Download .nbib Format: NLM
Optimizing Care for Patients With Adverse Events From Immunotherapeutics.

Cancer journal (Sudbury, Mass.)

Sheehan K, Price C, Hafez N.
PMID: 33298725
Cancer J. 2020 Nov/Dec;26(6):537-542. doi: 10.1097/PPO.0000000000000492.

Immune-related adverse events (irAEs) are a common occurrence in patients treated with immune checkpoint inhibitors. Fortunately, the majority of irAEs are mild and easily managed with steroids. As the use of immune checkpoint inhibitors and other immune therapies continues...

Cite
Sheehan K, Price C, Hafez N. Optimizing Care for Patients With Adverse Events From Immunotherapeutics. Cancer J. 2020;26(6):537-542doi: 10.1097/PPO.0000000000000492.
Sheehan, K., Price, C., & Hafez, N. (2020). Optimizing Care for Patients With Adverse Events From Immunotherapeutics. Cancer journal (Sudbury, Mass.), 26(6), 537-542. https://doi.org/10.1097/PPO.0000000000000492
Sheehan, Kelsey, et al. "Optimizing Care for Patients With Adverse Events From Immunotherapeutics." Cancer journal (Sudbury, Mass.) vol. 26,6 (2020): 537-542. doi: https://doi.org/10.1097/PPO.0000000000000492
Sheehan K, Price C, Hafez N. Optimizing Care for Patients With Adverse Events From Immunotherapeutics. Cancer J. 2020 Nov/Dec;26(6):537-542. doi: 10.1097/PPO.0000000000000492. PMID: 33298725.
Copy Download .nbib Format: NLM
[EDITORIAL. Changes in the practice of immunotherapy in Mexico: The new Clinical Practice Guidelines].

Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)

Becerril-Ángeles M.
PMID: 21967872
Rev Alerg Mex. 2011 Jan-Feb;58(1):1-2.

No abstract available.

Cite
Becerril-Ángeles M. EDITORIAL. Cambios en la inmunoterapia en México: La nueva Guía de Práctica Clínica. [EDITORIAL. Changes in the practice of immunotherapy in Mexico: The new Clinical Practice Guidelines]. Rev Alerg Mex. 2011;58(1):1-2
Becerril-Ángeles, M. (2011). EDITORIAL. Cambios en la inmunoterapia en México: La nueva Guía de Práctica Clínica. [EDITORIAL. Changes in the practice of immunotherapy in Mexico: The new Clinical Practice Guidelines]. Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993), 58(1), 1-2.
Becerril-Ángeles, Martín. "EDITORIAL. Cambios en la inmunoterapia en México: La nueva Guía de Práctica Clínica." [EDITORIAL. Changes in the practice of immunotherapy in Mexico: The new Clinical Practice Guidelines]. Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) vol. 58,1 (2011): 1-2.
Becerril-Ángeles M. EDITORIAL. Cambios en la inmunoterapia en México: La nueva Guía de Práctica Clínica. [EDITORIAL. Changes in the practice of immunotherapy in Mexico: The new Clinical Practice Guidelines]. Rev Alerg Mex. 2011 Jan-Feb;58(1):1-2. Spanish. PMID: 21967872.
Copy Download .nbib Format: NLM
Current strategies of virotherapy in clinical trials for cancer treatment.

Journal of medical virology

Lin W, Zhao Y, Zhong L.
PMID: 33738818
J Med Virol. 2021 Aug;93(8):4668-4692. doi: 10.1002/jmv.26947. Epub 2021 Apr 23.

As a novel immune-active agent for cancer treatment, viruses have the ability of infecting and replicating in tumor cells. The safety and efficacy of viruses has been tested and confirmed in preclinical and clinical trials. In the last decade,...

Cite
Lin W, Zhao Y, Zhong L. Current strategies of virotherapy in clinical trials for cancer treatment. J Med Virol. 2021;93(8):4668-4692doi: 10.1002/jmv.26947.
Lin, W., Zhao, Y., & Zhong, L. (2021). Current strategies of virotherapy in clinical trials for cancer treatment. Journal of medical virology, 93(8), 4668-4692. https://doi.org/10.1002/jmv.26947
Lin, Weijian, et al. "Current strategies of virotherapy in clinical trials for cancer treatment." Journal of medical virology vol. 93,8 (2021): 4668-4692. doi: https://doi.org/10.1002/jmv.26947
Lin W, Zhao Y, Zhong L. Current strategies of virotherapy in clinical trials for cancer treatment. J Med Virol. 2021 Aug;93(8):4668-4692. doi: 10.1002/jmv.26947. Epub 2021 Apr 23. PMID: 33738818.
Copy Download .nbib Format: NLM
Showing 85 to 94 of 94 entries